NXL · Nexalin Technology, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Management has evaluated these conditions and concluded that the Company does not currently have sufficient cash and cash equivalents to fund its anticipated operating requirements for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. Accordingly, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $217.16K | $301.65K | $168.72K | $110.75K | $1.32M | $144.07K | — | |
| -$2610 | -$8240 | -$3193 | $38.84K | — | — | — | |
| $30.06K | $61.37K | $36.59K | $25.69K | $363.21K | $21.44K | — | |
| $187.1K | $240.27K | $132.13K | $85.06K | $958.15K | $122.62K | — | |
| — | 79.65% | 78.31% | 76.8% | 72.51% | 85.12% | — | |
| $1.36M | $1.08M | $1.19M | $1.92M | $511K | $139K | $1.5M | |
| $3.48M | $3.13M | $2.55M | $2.37M | — | — | — | |
| $4.15M | $4.4M | $4.23M | $1.9M | $1.49M | $5.22M | — | |
| $31.36K | $21.54K | $15.11K | — | — | — | — | |
| $9.31M | $8.63M | $7.89M | $5.78M | $2.79M | $6.14M | — | |
| -$9.13M | -$8.39M | -$7.75M | -$5.7M | -$1.83M | -$6.02M | — | |
| — | -2781.69% | -4596.14% | -5143.48% | -138.72% | -4177.7% | — | |
| -$2610 | -$8240 | -$3193 | $38.84K | $59.38K | $82.32K | — | |
| $137.15K | $169.75K | $142.61K | $1.05M | $135.22K | -$59.4K | — | |
| -$8.99M | -$8.22M | -$7.61M | -$4.65M | — | — | — | |
| -$8.99M | -$8.22M | -$7.61M | -$4.65M | -$1.7M | -$6.08M | — | |
| — | -2725.76% | -4508.73% | -4197.56% | -128.49% | -4218.93% | — | |
| -$8.99M | -$8.22M | -$7.61M | -$4.69M | -$1.66M | -$6.08M | — | |
| USD/shares | -$0.47 | -$0.50 | -$0.83 | -$0.63 | -$0.30 | — | — |
| USD/shares | -$0.47 | -$0.50 | -$0.83 | -$0.63 | -$0.30 | — | — |
| shares | — | 16.39M | 9.22M | 7.36M | 5.57M | — | — |
| shares | — | 16.39M | 9.22M | 7.36M | 5.57M | — | — |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 51 similar-size Medical Devices companies (of 144 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| China | $190,301 | $85,248 | $3,614 | $1,207,816 | $26,132 |
| International | $190,301 | $85,248 | — | — | — |
| United States | $111,346 | $83,473 | $107,134 | $113,541 | $117,933 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Device Sales | $136,000 | $55,500 | — | $1,164,500 | $25,000 |
| Equipment | $89,042 | $37,826 | $27,299 | $26,778 | $15,218 |
| Licensing Fee | $49,114 | $69,501 | $82,080 | $79,188 | $102,910 |
| Other | $27,491 | $5,894 | $1,369 | $26,412 | $937 |
| Royalty Fee | — | — | — | $24,479 | — |